A 100% French nasal vaccine against SARS-CoV-2 to move into the clinical phase in 2022
In contrast to intramuscular vaccines, only nasal vaccines are able to block the virus in the nose by inducing local immunity in the nasal mucosa, i.e. the portal of entry and multiplication of the virus.
Saint Malo Recipharm Resyca Emily Henderson Manufacturing Organisation Val De Loire Regional Council Contract Development
Source: news-medical.net